PMID- 36851281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230301
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 11
IP  - 2
DP  - 2023 Feb 9
TI  - Associations of HLA Polymorphisms with Anti-SARS-CoV-2 Spike and Neutralizing 
      Antibody Titers in Japanese Rheumatoid Arthritis Patients Vaccinated with 
      BNT162b2.
LID - 10.3390/vaccines11020404 [doi]
LID - 404
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus 
      Disease 2019. Anti-SARS-CoV-2 spike (S) and neutralizing antibodies (Abs) are 
      measured to evaluate the efficacy of vaccines. Human leukocyte antigen (HLA) may 
      be associated with vaccine efficacy. Here, we investigated the association of HLA 
      polymorphisms with the production of anti-SARS-CoV-2 S or neutralizing Abs in 
      vaccinated rheumatoid arthritis (RA) patients in Japan. Genotyping of DRB1 and 
      DQB1 was conducted in 87 Japanese RA patients vaccinated with BNT162b2. 
      Associations of allele or haplotype carrier frequencies with anti-SARS-CoV-2 S or 
      neutralizing Abs were examined. DRB1*12:01 was significantly positively 
      associated with the production of S Ab (p = 0.0225, odds ratio [OR] 6.08, 95% 
      confidence interval [CI] 1.32-28.03). The DQB1*03:01 allele carrier frequency 
      tended to be higher in high responders of S Ab. Allele carrier frequencies of 
      DRB1*15:01 (p = 0.0102, OR 9.26, 95% CI 1.65-52.01) and DQB1*06:02 (p = 0.0373, 
      OR 7.00, 95% CI 1.18-41.36) were higher in responders of neutralizing Ab. 
      Haplotype and two-locus analyses of DRB1 and DQB1 suggested that DRB1 alleles 
      were the primary drivers of these associations. Logistic regression analysis 
      showed associations of these alleles independent of clinical characteristics. 
      Independent associations were found between HLA alleles and anti-SARS-CoV-2 Ab 
      production by vaccinated RA patients.
FAU - Higuchi, Takashi
AU  - Higuchi T
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
AD  - Department of Nephrology, Ushiku Aiwa General Hospital, 896 Shishiko-cho, Ushiku 
      300-1296, Japan.
FAU - Oka, Shomi
AU  - Oka S
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
FAU - Furukawa, Hiroshi
AU  - Furukawa H
AUID- ORCID: 0000-0003-1353-8056
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
FAU - Tohma, Shigeto
AU  - Tohma S
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
LA  - eng
GR  - National Hospital Organization/
GR  - Bristol-Myers Squibb Co/
GR  - Abbott Japan Co., Ltd./
GR  - Astellas Pharma Inc./
GR  - Chugai Pharmaceutical Co., Ltd./
GR  - Eisai Co., Ltd./
GR  - Mitsubishi Tanabe Pharma Corporation/
GR  - Merck Sharp and Dohme Inc./
GR  - Pfizer Japan Inc./
GR  - Takeda Pharmaceutical Company Limited/
GR  - Teijin Pharma Limited/
PT  - Journal Article
DEP - 20230209
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC9965868
OTO - NOTNLM
OT  - HLA
OT  - anti-SARS-CoV-2 neutralizing antibody
OT  - anti-SARS-CoV-2 spike antibody
OT  - rheumatoid arthritis
OT  - vaccination
COIS- H.F. was supported by research grants from Bristol-Myers Squibb Co. H.F. received 
      honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo 
      Pharma Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Company. S.T. was 
      supported by research grants from nine pharmaceutical companies: Abbott Japan 
      Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., 
      Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer 
      Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. 
      S.T. received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma 
      Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., 
      Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc. The other authors 
      declare no financial or commercial conflict of interest.
EDAT- 2023/03/01 06:00
MHDA- 2023/03/01 06:01
PMCR- 2023/02/09
CRDT- 2023/02/28 01:32
PHST- 2022/12/27 00:00 [received]
PHST- 2023/01/23 00:00 [revised]
PHST- 2023/02/08 00:00 [accepted]
PHST- 2023/02/28 01:32 [entrez]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/03/01 06:01 [medline]
PHST- 2023/02/09 00:00 [pmc-release]
AID - vaccines11020404 [pii]
AID - vaccines-11-00404 [pii]
AID - 10.3390/vaccines11020404 [doi]
PST - epublish
SO  - Vaccines (Basel). 2023 Feb 9;11(2):404. doi: 10.3390/vaccines11020404.